MedTrace Logo

Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

NCT05954780 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-01-14

No results posted yet for this study

Summary

The non-interventional study SEATTLE aims to answer open scientific questions regarding QoL and tolerability/safety and AE management of selinexor as well as effectiveness and dosing in clinical routine. Thus, SEATTLE will provide real-world evidence complementary to pivotal studies.

Conditions

Interventions

DRUG

Selinexor

Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC

Sponsors & Collaborators

  • Menarini Stemline

    collaborator UNKNOWN

  • Climedo Health GmbH

    collaborator UNKNOWN

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Tobias Dechow, Prof. Dr. · Gemeinschaftspraxis für Hämatologie und Onkologie GbR

  • Maria Krauth, Assoc. Prof. PD Dr. · Universitätsklinikum AKH Wien

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-28
Primary Completion
2026-10-30
Completion
2026-10-30

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05954780 on ClinicalTrials.gov